Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

23 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia.

Sanford Burnham Prebys Medical Discovery Institute

Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators.

Sanford Burnham Prebys Medical Discovery Institute

Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma.

Sanford Burnham Prebys Medical Discovery Institute

1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists.

Sanford Burnham Prebys Medical Discovery Institute

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.

Sanford Burnham Prebys Medical Discovery Institute

Discovery of Imidazo[1,2-

Sanford Burnham Prebys Medical Discovery Institute

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor.

Sanford Burnham Prebys Medical Discovery Institute

Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors.

Sanford Burnham Prebys Medical Discovery Institute

PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR

Jiangsu Hengrui Pharmaceuticals

CELL-POTENT BISUBSTRATE INHIBITORS FOR NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF

Purdue Research Foundation

Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses

Shanghai AB Pharmatech

NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS

Italfarmaco

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Achillion Pharmaceuticals

Human plasma kallikrein inhibitors

Biocryst Pharmaceuticals

Triazolo-azepine derivatives

Hoffmann-La Roche

1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors

H. Lundbeck

TRPV4 antagonists

Glaxosmithkline Intellectual Property Development

Carboxylic acid compounds

Sumitomo Dainippon Pharma

Hydantoin derivative

Chugai Seiyaku Kabushiki Kaisha

Benzoxazinone amides as mineralocorticoid receptor modulators

Astrazeneca

Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity.

Peking University

Aminopyrimidine derivatives as LRRK2 modulators

Genentech

Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.

Shandong University